IPO - Curanex Pharmaceuticals Inc

Form Type: S-1/A

Filing Date: 2025-03-17

Corporate Action: Ipo

Type: New

Accession Number: 000149315225010520

Filing Summary: Curanex Pharmaceuticals Inc is filing an S-1/A registration statement for an initial public offering (IPO) to sell 2,000,000 shares of Common Stock and 1,750,000 shares for resale by stockholders. The offering price is estimated to range between $4.00 to $6.00 per share. The company intends to list on the Nasdaq under the symbol 'CURX'. Following the merger procedure completed on June 10, 2024, which transitioned the company from New York to Nevada, Curanex has established a developmental platform focused on botanical drugs for inflammatory diseases. Their lead candidate, Phyto-N, is aimed at addressing several major medical conditions. This IPO marks their first public offering and indicates a significant step in their corporate growth, intended to enhance funding for ongoing research and development. Regulatory risks are acknowledged due to the complexities involved in bringing botanical drugs to market, a challenge underscored by the limited approvals of such drugs by the FDA historically. The corporate structure post-IPO will see the founders retain approximately 73.9% voting power.

Document Link: View Document

Form Type: S-1/A

Filing Date: 2025-02-14

Corporate Action: Ipo

Type: New

Accession Number: 000149315225006655

Filing Summary: Curanex Pharmaceuticals Inc., a Nevada corporation, filed an amended registration statement for an initial public offering (IPO) of 3,750,000 shares of common stock. The registration includes 2,000,000 shares offered on a firm commitment basis by underwriters and up to 1,750,000 shares for resale by selling stockholders. The expected offering price per share is between $4.00 and $6.00, with the midpoint assumed at $5.00, generating estimated proceeds of $10,000,000. The document provides insights into the company's focus on developing botanical drugs for treating inflammatory diseases, including an overview of their lead drug candidate, Phyto-N. The filing also reflects a structural change with the merger of the predecessor company under New York law into a Nevada subsidiary, and outlines the potential risks and operations involved in the public offering as well as Curanex's future business outlook. The company highlights high investment risks, controlled corporate governance status, and its status as an emerging growth company with reduced reporting requirements.

Document Link: View Document

Form Type: DRS/A

Filing Date: 2024-09-16

Corporate Action: Ipo

Type: New

Accession Number: 000149315224036252

Filing Summary: Curanex Pharmaceuticals Inc is filing a confidential Draft Registration Statement for an initial public offering (IPO) under the Securities Act of 1933. The filing reflects a firm commitment to sell shares of common stock, estimated to raise between $5 million and $30 million in gross proceeds. The company, which has transitioned from being known as Durand Damiel Health Inc and then Fordman Pharma Inc, focuses on producing innovative botanical drugs for treating inflammatory diseases. Curanex's founders beneficially own approximately 80% of the outstanding shares and control voting powers. The company has plans for listing its shares on The Nasdaq Capital Market. The registration is aimed at achieving compliance with regulatory requirements, with no public market currently established for its common stock. Curanex’s lead drug candidate, Phyto-N, intends to address multiple inflammatory conditions, and the company anticipates submitting an Investigational New Drug application for this candidate by 2025. Furthermore, the associated risks, the timeline for development, and details regarding underwriter agreements are outlined, reflecting a comprehensive approach to financing and regulatory compliance as the company steps into public markets.

Document Link: View Document

Form Type: DRS/A

Filing Date: 2024-08-15

Corporate Action: Ipo

Type: New

Accession Number: 000149315224032472

Filing Summary: Curanex Pharmaceuticals Inc is submitting a Draft Registration Statement as part of a planned initial public offering (IPO) to commence as soon as practicable after the effective date. This prospectus outlines the company's transformation, including its new focus on botanical drugs for inflammatory diseases, recent mergers, and asset purchases, notably the acquisition of patent applications and studies from Duraviva Pharma Inc. The company aims to address significant unmet medical needs while leveraging a proprietary extraction and optimization platform. Founders hold a significant ownership stake, and the company has acknowledged the potential challenges in obtaining regulatory approvals for botanical drugs. This preliminary offering seeks approximately $5 million to $30 million, with the shares aiming to be listed on The Nasdaq Capital Market. The document discusses company operations, risks, and the implications of being an emerging growth company, smaller reporting company, and controlled company under corporate governance standards, emphasizing that investment in its common stock carries a high risk due to numerous factors.

Document Link: View Document

Form Type: DRS

Filing Date: 2024-06-20

Corporate Action: Ipo

Type: New

Accession Number: 000149315224024532

Filing Summary: Curanex Pharmaceuticals Inc has confidentially submitted a Draft Registration Statement to the SEC for an initial public offering (IPO) under the Jumpstart Our Business Startups Act on June 20, 2024. The Registration Statement is intended to register shares of common stock with anticipated gross proceeds between $5 million and $30 million. The offering represents a significant step for Curanex, which has transitioned from a New York to a Nevada corporation, enhancing its operational focus on developing innovative botanical drugs for treating inflammatory diseases. Curanex plans to complete the offering as soon as practicable after the effective date of the Registration Statement, with a proposed market listing on The Nasdaq Capital Market. This IPO marks a pivotal moment for Curanex, particularly given its strategic asset purchase agreement with Duraviva Pharma, where it acquired essential intellectual property assets crucial for its drug development pipeline, including its lead candidate, Phyto-N. Curanex is emerging as a significant player in the pharmaceutical field, targeting unmet medical needs in various diseases, including ulcerative colitis and diabetes. The company remains classified as an emerging growth company and smaller reporting company under federal laws, allowing it to follow reduced reporting requirements, which may influence its investor transparency during the IPO process.

Document Link: View Document